| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.MP.4000425 |
| P698 | PubMed publication ID | 9857976 |
| P50 | author | Francesco Benedetti | Q38545632 |
| Enrico Smeraldi | Q72933640 | ||
| P2093 | author name string | M Catalano | |
| D Di Bella | |||
| J Perez | |||
| R Zanardi | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluvoxamine | Q409236 |
| serotonin | Q167934 | ||
| P304 | page(s) | 508-511 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine | |
| P478 | volume | 3 |
| Q34074197 | 5-HT-HPA interactions in two models of transgenic mice relevant to major depression |
| Q34264739 | 5-HTTLPR polymorphism impacts task-evoked and resting-state activities of the amygdala in Han Chinese |
| Q37102263 | A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment |
| Q44175726 | A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine |
| Q44594245 | Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics |
| Q44300554 | Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). |
| Q43590767 | Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. |
| Q42485885 | Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study |
| Q45956855 | Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. |
| Q31135283 | Anterior cingulate dysfunction in geriatric depression |
| Q44598160 | Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene |
| Q34088515 | Antidepressant response and the serotonin transporter gene-linked polymorphic region |
| Q73179152 | Antidepressant selection in the postgenomic era |
| Q44440922 | Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism |
| Q36248038 | Antidepressant-induced manic conversion: a developmentally informed synthesis of the literature |
| Q46611107 | Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene |
| Q35036686 | Arguments for the genetic basis of the bipolar spectrum |
| Q34201923 | Association between a serotonin transporter gene variant and hopelessness among men in the Heart and Soul Study |
| Q43882789 | Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion |
| Q37254532 | Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder. |
| Q33806771 | Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression |
| Q35984750 | Association of Anxiety Symptoms in Offspring of Bipolar Parents with Serotonin Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype |
| Q34348095 | Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans |
| Q37074636 | Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users |
| Q36018468 | Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study |
| Q34316695 | Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy |
| Q44634481 | Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response |
| Q44245157 | Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders |
| Q42347338 | Authors' response to "Maternal age as a potential explanation of the role of the L allele of the serotonin transporter gene in anxiety and depression in Asians". |
| Q47958150 | BDNF, relative preference, and reward circuitry responses to emotional communication |
| Q36713109 | Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study |
| Q37582410 | Biological variations in depression and anxiety between East and West. |
| Q60641089 | Cautionary note: complex (dys)function of the serotonin transporter |
| Q51481116 | Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants. |
| Q27004154 | Clinical and molecular genetics of psychotic depression |
| Q46666799 | Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism |
| Q37255370 | Clinical implications of genetic variation in the serotonin transporter promoter region: a review |
| Q44628774 | Comorbidity of alcohol dependence with attention-deficit hyperactivity disorder: differences in phenotype with increased severity of the substance disorder, but not in genotype (serotonin transporter and 5-hydroxytryptamine-2c receptor). |
| Q36983850 | Correlation of 5-HTT, BDNF and NPSR1 gene polymorphisms with anxiety and depression in asthmatic patients |
| Q34396635 | Culture and psychopharmacology |
| Q33234706 | Detection and characterization of DNA variants in the promoter regions of hundreds of human disease candidate genes |
| Q28609425 | Developing novel treatments for mood disorders: accelerating discovery |
| Q46197985 | Differential effects of 5-HTTLPR genotypes on mood, memory, and attention bias following acute tryptophan depletion and stress exposure |
| Q73384138 | Differential tissue distribution of the enantiomers of racemic pindolol in the rat |
| Q43725413 | Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders |
| Q94010427 | Dosing and Monitoring: Children and Adolescents |
| Q35826495 | Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). |
| Q36864041 | Drug development for CNS disorders: strategies for balancing risk and reducing attrition |
| Q33655082 | Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder |
| Q35692269 | Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials |
| Q44588970 | Effects of rapid tryptophan depletion on mood and urge to drink in patients with co-morbid major depression and alcohol dependence |
| Q45049144 | Effects of serotonin transporter promoter polymorphisms on serotonin function |
| Q35988130 | Emerging strategies and applications of pharmacogenomics |
| Q35040746 | Ethnic differences in antidepressant response: a prospective multi-site clinical trial |
| Q34585242 | Evaluation of the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene in females with postpartum depression |
| Q43728696 | Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression |
| Q35012645 | Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects |
| Q35680883 | From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes |
| Q35709598 | From monoamines to genomic targets: a paradigm shift for drug discovery in depression |
| Q37660158 | From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders |
| Q27015830 | From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment |
| Q43585236 | Functional polymorphism within the promotor of the serotonin transporter gene is associated with severe hyperkinetic disorders |
| Q34435115 | Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism |
| Q44866370 | Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. |
| Q36717718 | GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol |
| Q36070320 | Gender moderates the relationship between mania spectrum and serotonin transporter polymorphisms in depression |
| Q37971344 | Gene-environment interaction in major depression and antidepressant treatment response |
| Q36103263 | Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model(1,2) |
| Q34117532 | Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development. |
| Q34530084 | Genetic factors and treatment of mood disorders |
| Q34467017 | Genetic perspectives on the serotonin transporter |
| Q28543005 | Genetic prediction of antidepressant drug response and nonresponse in Korean patients |
| Q36206096 | Genetics and psychopharmacology: prospects for individualized treatment. |
| Q43946813 | Genetics of bipolar disorders |
| Q24654656 | Genetics of migraine and pharmacogenomics: some considerations |
| Q36973699 | Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response |
| Q34448376 | Hepatitis C, interferon a and depression: main physiopathologic hypothesis |
| Q44487762 | High platelet-serotonin uptake activity is associated with a rapid response in depressed patients treated with amitriptyline |
| Q34589831 | How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches |
| Q33892493 | How possible is the development of an operational psychometric method to assess the presence of the 5-HTTLPR s allele? Equivocal preliminary findings |
| Q45081687 | Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant |
| Q35834300 | Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter |
| Q33404025 | Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. |
| Q35104346 | Indianizing psychiatry - Is there a case enough? |
| Q46385107 | Individual differences in threat sensitivity predict serotonergic modulation of amygdala response to fearful faces |
| Q60183059 | Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications |
| Q37089253 | Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications |
| Q43751897 | Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders |
| Q41452983 | Influence of 5-HTTLPR genotypes on structural and functional connectivity within amygdala-prefrontal cortex circuitry |
| Q35705858 | Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. |
| Q43870679 | Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. |
| Q46555929 | Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder |
| Q43722419 | Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. |
| Q43975771 | Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome |
| Q50082143 | Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy. |
| Q52891518 | Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. |
| Q35182336 | Involvement of serotonin transporter gene polymorphisms (5-HTT) in impulsive behavior in the japanese population |
| Q49122438 | Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? |
| Q35111565 | Is treatment-resistant depression a unique subtype of depression? |
| Q48041301 | Kynurenine pathway and white matter microstructure in bipolar disorder |
| Q30499812 | Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression |
| Q44412271 | Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study |
| Q43783004 | Marker gene polymorphisms in hyperkinetic disorder--predictors of clinical response to treatment with methylphenidate? |
| Q36673952 | Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients |
| Q28307770 | Molecular actions and clinical pharmacogenetics of lithium therapy |
| Q34137588 | Molecular genetic and family studies in affective disorders: state of the art. |
| Q87456699 | Molecular genetic findings in mood disorders |
| Q34146169 | Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders |
| Q46911907 | Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy |
| Q24792166 | Neural network analysis in pharmacogenetics of mood disorders |
| Q26830563 | Neurogenetics of depression: a focus on reward processing and stress sensitivity |
| Q34560707 | Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram |
| Q34014377 | New advances in pharmacogenomics |
| Q43868516 | New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies |
| Q43812368 | No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors |
| Q33695747 | Novel strategies for pharmacotherapy of depression |
| Q33183862 | Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. |
| Q44278023 | Overexpression of an epitope-tagged serotonin transporter in serotonin neurons of the dorsal raphe nucleus using a defective HSV-1 vector |
| Q35730488 | Pathophysiologic findings of irritable bowel syndrome in china |
| Q34726454 | Personalized medicine in psychiatry: problems and promises |
| Q48244859 | Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. |
| Q35645901 | Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing |
| Q34453112 | Pharmacogenetic screening and therapeutic drugs |
| Q36904466 | Pharmacogenetic studies in depression: a proposal for methodologic guidelines |
| Q35707704 | Pharmacogenetics and psychiatry |
| Q34116530 | Pharmacogenetics and the serotonin system: initial studies and future directions. |
| Q34574406 | Pharmacogenetics in affective disorders |
| Q35038056 | Pharmacogenetics in drug development |
| Q36460262 | Pharmacogenetics in mood disorder |
| Q37076472 | Pharmacogenetics in psychiatry: are we ready for widespread clinical use? |
| Q34155796 | Pharmacogenetics of antidepressant response |
| Q35026088 | Pharmacogenetics of antidepressants |
| Q28252209 | Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response |
| Q34577185 | Pharmacogenetics of bipolar disorder |
| Q28216643 | Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants |
| Q35207551 | Pharmacogenetics of monoamine transporters |
| Q34286003 | Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy |
| Q35237038 | Pharmacogenomic strategy for individualizing antidepressant therapy |
| Q47657960 | Pharmacogenomic testing in child and adolescent psychiatry: An evidence-based review |
| Q36019193 | Pharmacogenomics and systems biology of membrane transporters |
| Q37678047 | Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms |
| Q90745539 | Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? |
| Q35237236 | Pharmacogenomics of antidepressant treatment effects |
| Q35805941 | Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome |
| Q34134861 | Pharmacogenomics of psychiatric disorders |
| Q89329295 | Pharmacogenomics: A focus on antidepressants and atypical antipsychotics |
| Q35090217 | Pharmacogenomics: marshalling the human genome to individualise drug therapy |
| Q36008105 | Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. |
| Q28236448 | Platelet MAO activity and the 5-HTT gene promoter polymorphism are associated with impulsivity and cognitive style in visual information processing |
| Q46769754 | Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy |
| Q36095772 | Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. |
| Q48588111 | Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. |
| Q35237042 | Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. |
| Q34543502 | Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder |
| Q36593806 | RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis |
| Q44311645 | Rat strain differences in peripheral and central serotonin transporter protein expression and function |
| Q32144286 | Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. |
| Q33642413 | Recent advances in predicting responses to antidepressant treatment |
| Q34976865 | Receptor pharmacogenetics: relevance to CNS syndromes |
| Q73046888 | Regression to the truth: replication of association in pharmacogenetic studies |
| Q33945106 | Research and treatment approaches to depression |
| Q37206381 | Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression |
| Q40370839 | Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. |
| Q34871885 | Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder |
| Q42595600 | Role of COMT, 5-HT(1A) , and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation |
| Q35078269 | Role of pharmacogenomics in individualising treatment with SSRIs |
| Q37437784 | SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. |
| Q33302969 | Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research |
| Q33710367 | Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans |
| Q31925050 | Serotonergic gene expression and depression: implications for developing novel antidepressants. |
| Q36679249 | Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. |
| Q37229060 | Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder |
| Q36248063 | Serotonin firing activity as a marker for mood disorders: lessons from knockout mice |
| Q48048080 | Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients |
| Q43932430 | Serotonin transporter gene associated with lithium prophylaxis in mood disorders. |
| Q34369115 | Serotonin transporter gene polymorphisms and chronic illness of depression |
| Q48628669 | Serotonin transporter genotype and function in relation to antidepressant response in Koreans |
| Q36491587 | Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients |
| Q46531752 | Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. |
| Q35750662 | Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion |
| Q44628316 | Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment |
| Q51905107 | Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. |
| Q43852512 | Serotonin transporter promoter genotype and illness recurrence in mood disorders |
| Q33921338 | Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. |
| Q44357536 | Serotonin-related gene polymorphisms and central nervous system serotonin function |
| Q33718672 | Sleep deprivation in depression: what do we know, where do we go? |
| Q42771386 | Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression. |
| Q46703927 | Stop signal response inhibition is not modulated by tryptophan depletion or the serotonin transporter polymorphism in healthy volunteers: implications for the 5-HT theory of impulsivity |
| Q46748770 | Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test |
| Q61479738 | Strain-dependent neurochemical and neuroendocrine effects of desipramine, but not fluoxetine or imipramine, in Spontaneously Hypertensive and Wistar–Kyoto rats |
| Q37911004 | Surrogate markers of treatment outcome in major depressive disorder |
| Q83207472 | Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response |
| Q48005756 | The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression |
| Q60501981 | The Behavioral Genetics of Serotonin: Relevance to Anxiety and Depression |
| Q51846528 | The Promise and Reality of Pharmacogenetics in Psychiatry |
| Q39337639 | The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients |
| Q45134478 | The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression |
| Q33707758 | The challenges of psychopharmacogenetics |
| Q38579133 | The clinical pharmacology of depressive states |
| Q36978299 | The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls |
| Q89959099 | The increasing challenge of the possible impact of ethnicity on psychopharmacology |
| Q33654737 | The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder |
| Q41452962 | The long rather than the short allele of 5-HTTLPR predisposes Han Chinese to anxiety and reduced connectivity between prefrontal cortex and amygdala |
| Q34663662 | The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis |
| Q77805824 | The pharmacogenomics of depression |
| Q35757723 | The pharmacogenomics of selective serotonin reuptake inhibitors. |
| Q35226451 | The promise and reality of pharmacogenetics in psychiatry |
| Q60536553 | The serotonin transporter and clozapine response |
| Q34227903 | The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder |
| Q48717410 | Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. |
| Q43764520 | Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. |
| Q34435136 | Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs |
| Q35630029 | Watson and Crick 50 years on. From double helix to pharmacogenomics |
| Q85907009 | [Serotonin transporter gene and stress reactivity in unipolar depression. Role of the HPA system as endophenotype of the SLC6A4 gene] |
Search more.